Leaders with CureDuchenne say approvals are expected this year for several new treatments for Duchenne MD, making it "an ...

All muscular dystrophies cause muscle weakness, but life expectancy can vary dramatically between types of muscular dystrophy.

By Mariam Sunny Jan 26 (Reuters) - Sarepta Therapeutics' gene therapy for Duchenne muscular dystrophy slowed disease ...

Sarepta says effects of Duchenne muscular dystrophy gene therapy were durable three years after treatment; More biotech ...

Dr. Mackey’s project, “ Regenerating healthy human skeletal muscle at single nucleus resolution ,” will create the most detailed molecular map to date of how healthy human muscle repairs itself. The ...

New York, Jan. 26, 2026 (GLOBE NEWSWIRE) -- In recognition of Rare Disease Day on February 28, the Muscular Dystrophy Association (MDA) is sharing powerful community stories throughout the month that ...

After a spate of patient deaths in 2025 linked to the company’s Duchenne gene therapy, Sarepta shared new data showing benefits of the therapy three years after dosing.

Panelists discuss how data from MDA 2025 demonstrate that delandistrogene moxeparvovec (gene therapy for DMD) shows statistically significant improvements in motor function outcomes including North ...

Muscular dystrophy, known as DMD, is a rare and fatal genetic disease that primarily affects boys, slowly robbing them of their ability to walk, breathe and live independently. Until now, there have ...

Editor’s note: This is an automatically generated transcript. Please notify [email protected] if there are concerns regarding accuracy of the transcription. Muscular dystrophy, as a category, is quite ...

Minnesota (WCCO) -- An 8-year-old northern Minnesota boy is one of the first in the country to receive a specific type of gene therapy treatment. Colton Belluzzo was diagnosed with a form of muscular ...